| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8651023 | American Heart Journal | 2018 | 22 Pages |
Abstract
In an mITT analysis of all patients administered study drug, extended-duration betrixaban reduced the primary end point as well as symptomatic events. In an as-treated analysis, 80 mg of betrixaban reduced VTE-related death.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
C. Michael MS, MD, Tarek MD, Megan K. MPH, Gerald MD, Serge MD, Yazan MD, Fahad MD, Mathieu MD, Samuel Z. MD, Russel MBBS, Adrian F. MD, Alexander T. MD, Robert A. MD,